1-[(3,5-Dichloro-4-isocyanatophenyl)methyl]-4-methylsulfonylpiperazine | 1092069-77-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(3,5-Dichloro-4-isocyanatophenyl)methyl]-4-methylsulfonylpiperazine
• CAS: 1092069-77-6
• 化学式: C₁₃H₁₅Cl₂N₃O₃S
• 分子量: 364.252
• InChiKey: XOQIHYMOTIANRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  78.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[(3,5-Dichloro-4-isocyanatophenyl)methyl]-4-methylsulfonylpiperazine 、 2-(4-methoxyphenyl)-N-(4-(piperazin-1-yl)phenyl)acetamide methanesulfonate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 39.0h， 以48%的产率得到N-[2,6-dichloro-4-[(4-methylsulfonylpiperazin-1-yl)methyl]phenyl]-4-[4-[[2-(4-methoxyphenyl)acetyl]amino]phenyl]piperazine-1-carboxamide
  参考文献：
  名称：

  WO2008/148868

  摘要：

  公开号：
• 作为产物：
  描述：

  1,3-Dichloro-5-methyl-2-(2,2,2-trichloroethyl)benzene 在 盐酸 、 lithium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 氰基磷酸二乙酯 、 水 、 sodium 、 三乙胺 作用下， 以 甲醇 、 四氯化碳 、 乙醚 、 二氯甲烷 、 乙腈 为溶剂， 反应 39.91h， 生成 1-[(3,5-Dichloro-4-isocyanatophenyl)methyl]-4-methylsulfonylpiperazine
  参考文献：
  名称：

  WO2008/148868

  摘要：

  公开号：

文献信息

• PIPERIDINE/PIPERAZINE DERIVATIVES
  申请人：Bongartz Jean-Pierre Andre Marc

  公开号：US20100190789A1

  公开（公告）日：2010-07-29

  The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NR x —C(═O)—; —Z 1 —C(O)—; —Z 1 —NR x —C(═O)—; —C(═O)—Z 1 —; —NR x —C(═O)—Z 1 —; —S(═O)p-; —C(═S)—; —NR x —C(═S)—; —Z 1 —C(═S)—; —Z 1 —NR x —C(═S)—; —C(═S)—Z1-; NR x —C(═S)—Z—; Y represents NR x —C(= 0 )-Z 2 —; —NR x —C(= 0 )-Z 2 —NR y —; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )—; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )-; O—; —NR x —C(= 0 )-Z 2 - 0 -; —NR x —C(= 0 )-Z 2 - 0 -C(= 0 )-; —NR x —C(= 0 )-Z 2 —C(= 0 )-; —NR x —C(= 0 )-Z 2 —C(= 0 )-; —NR x —C(= 0 )- 0 -Z 2 —C(= 0 )-; —NR x —C(= 0 )- 0 -Z 2 —C(= 0 )- 0 -; —NR x —C(═O)—O—Z 2 —O—C(═O)—; —NR x —C(═O)—Z 2 —C(═O)—NR y —; —NR x —C(═O)—Z 2 —NR y —C(= 0 )-NR y —; —C(═O)—Z 2 —; —C(═O)—Z 2 —O—; —C(= 0 )-NR x —Z 2 —; —C(= 0 )-NR x —Z 2 - 0 -; —C(= 0 )-NR x —Z 2 —C(= 0 )- 0 -; —C(= 0 )-NR x —Z 2 - 0 -C(= 0 )-; —C(= 0 )-NR x —Z 2 —NR y —; —C(= 0 )—NR x —Z 2 —NR y —C(= 0 )-; —C(= 0 )-NR x —Z 2 —NR y —C(= 0 )- 0 -; R 1 represents C 1-12 alkyl optionally substituted with cyano, C 1-4 alkyloxy, C 1-4 alkyl-oxyC 1-4 alkyloxy, C 3-6 Cycloalkyl or aryl; C 2-6 alkenyl; C 2-6 alkynyl; C 3-6 cycloalkyl; adamantanyl; aryl 1 ; aryl 1 C 1-6 alkyl; Het 1 ; or Het 1 C 1-6 alkyl; provided that when Y represents —NR x —C(═O)—Z 2 —; —NR x —C(= 0 )-Z 2 —NR y ; —NR x —C(═O)—Z 2 —C(═O)—NR y —; —C(═O)—Z 2 —; —NR x —C(= 0 )-Z 2 —NR y —C(= 0 )—NR y —; —C(═O)—NR—Z 2 —; —C(═O)—NR—O—Z 2 —; or —C(= 0 )-NR x —Z 2 —NR y —; then R 1 may also represent hydrogen; R 2 represents hydrogen, C 1-12 alkyl, C 2-6 alkenyl or R 3 ; provided that if X represents —O—C(═O)—; the R 2 O represents R 3 ; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
• US8981094B2
  申请人：——

  公开号：US8981094B2

  公开（公告）日：2015-03-17
• [EN] PIPERIDINE/PIPERAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPERIDINE/PIPERAZINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2008148868A1

  公开（公告）日：2008-12-11

  [EN] The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NRx-C(=O)-; -Z1-C(O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(=O)-Z1-; -S(=O)p-; -C(=S)-; -NRx-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(=S)-Z1-; Y represents NRx-C(=0)- Z2-; -NRx-C(=0)-Z2-NRy-; -NRx-C(=0)-Z2-NRy-C(=0)-; -NRx-C(=0)-Z2-NRy-C(=0)- O-; -NRx-C(=0)-Z2-0-; -NRx-C(=0)-Z2-0-C(=0)-; -NRx-C(=0)-Z2-C(=0)-; -NRx-C(=0)-Z2-C(=0)-0-; -NRx-C(=0)-0-Z2-C(=0)-; -NRx-C(=0)-0-Z2-C(=0)-0-; -NRx-C(=O)-O-Z2-O-C(=O)-; -NRx-C(=O)-Z2-C(=O)-NRy-; -NRx-C(=O)-Z2-NRy- C(=0)-NRy-; -C(=O)-Z2-; -C(=O)-Z2-O-; -C(=0)-NRx-Z2-; -C(=0)-NRx-Z2-0-; -C(=0)-NRx-Z2-C(=0)-0-; -C(=0)-NRx-Z2-0-C(=0)-; -C(=0)-NRx-0-Z2-; -C(=O)- NRx-Z2-NRy-; -C(=0)-NRx-Z2-NRy-C(=0)-; -C(=0)-NRx-Z2-NRy-C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cy cloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents -NRX-C(=O)-Z2-; -NRx-C(=0)-Z2-NRy; -NRX-C(=O)-Z2-C(=O)- NRy-; -C(=O)-Z2-; -NRx-C(=0)-Z2-NRy-C(=0)-NRy-; -C(=O)-NRX-Z2-; -C(=O)-NRX- O-Z2-; or -C(=0)-NRx-Z2-NRy-; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents -O-C(=O)-, then R2 represents R3; and provided that is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
  [FR] L'invention concerne un inhibiteur de DGAT représenté par la formule (I), comprenant n'importe quelle forme stéréochimiquement isomère de celui-ci. Dans cette formule A représente CH ou N, la ligne en pointillé représente une liaison optionnelle dans le cas où A représente un atome de carbone, X représente -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NRx-C(=O)-; -Z1-C(O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(=O)-Z1-; -S(=O)p-; -C(=S)-; -NRx-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(=S)-Z1-; Y représente NRx-C(=0)- Z2-; -NRx-C(=0)-Z2-NRy-; -NRx-C(=0)-Z2-NRy-C(=0)-; -NRx-C(=0)-Z2-NRy-C(=0)- O-; -NRx-C(=0)-Z2-0-; -NRx-C(=0)-Z2-0-C(=0)-; -NRx-C(=0)-Z2-C(=0)-; -NRx-C(=0)-Z2-C(=0)-0-; -NRx-C(=0)-0-Z2-C(=0)-; -NRx-C(=0)-0-Z2-C(=0)-0-; -NRx-C(=O)-O-Z2-O-C(=O)-; -NRx-C(=O)-Z2-C(=O)-NRy-; -NRx-C(=O)-Z2-NRy- C(=0)-NRy-; -C(=O)-Z2-; -C(=O)-Z2-O-; -C(=0)-NRx-Z2-; -C(=0)-NRx-Z2-0-; -C(=0)-NRx-Z2-C(=0)-0-; -C(=0)-NRx-Z2-0-C(=0)-; -C(=0)-NRx-0-Z2-; -C(=O)- NRx-Z2-NRy-; -C(=0)-NRx-Z2-NRy-C(=0)-; -C(=0)-NRx-Z2-NRy-C(=0)-0-; R1 représente C1-12alkyle éventuellement substitué avec cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cy cloalkyle ou aryle; C2-6alkenyle; C2-6alkynyle; C3-6cycloalkyle; adamantanyle; aryle1; aryle1C1-6alkyle; Het1; ou Het1C1-6alkyle; sous réserve que quand Y représente -NRX-C(=O)-Z2-; -NRx-C(=0)-Z2-NRy; -NRX-C(=O)-Z2-C(=O)- NRy-; -C(=O)-Z2-; -NRx-C(=0)-Z2-NRy-C(=0)-NRy-; -C(=O)-NRX-Z2-; -C(=O)-NRX- O-Z2-; or -C(=0)-NRx-Z2-NRy-; alors R1 peut aussi représenter hydrogène; R2 représentes hydrogène, C1-12alkyle, C2-6alkenyle ou R3; sous réserve que si X représente -O-C(=O)-, alors R2 represents R3; et sous réserve que (voir formule dans l'abrégé en anglais) soit exclu;; L'invention concerne aussi un N-oxyde de ce composé, un sel pharmaceutiquement acceptable ou un solvate de ce composé. L'invention concerne aussi des procédés de préparation de ces composés, des compositions pharmaceutiques comprenant ces composés ainsi que l'utilisation de ces composés comme médecine.
• WO2008/148868
  申请人：——

  公开号：——

  公开（公告）日：——